REVIVA PHARMACEUTICALS HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REVIVA PHARMACEUTICALS HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.86M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($29.92M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($39.26M) | Apr 3, 2025 |
| FY2023 | Sep 30, 2023 | ($11.35M) | Apr 15, 2024 |
| FY2023 | Jun 30, 2023 | ($11.71M) | Apr 15, 2024 |
| FY2023 | Mar 31, 2023 | ($6.85M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($28.26M) | Apr 15, 2024 |
| FY2023 | Sep 30, 2022 | ($5.45M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($8.52M) | Mar 30, 2023 |
| FY2021 | Dec 13, 2021 | ($8.52M) | Mar 15, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.20M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($30.80M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($39.50M) | Apr 3, 2025 |
| FY2023 | Sep 30, 2023 | ($11.56M) | Apr 15, 2024 |
| FY2023 | Jun 30, 2023 | ($11.34M) | Apr 15, 2024 |
| FY2023 | Mar 31, 2023 | ($6.98M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($28.23M) | Apr 15, 2024 |
| FY2023 | Sep 30, 2022 | ($5.50M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($10.10M) | Mar 30, 2023 |
| FY2021 | Dec 13, 2021 | ($10.10M) | Mar 15, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.71M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $22.91M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $31.42M | Apr 3, 2025 |
| FY2023 | Sep 30, 2023 | $9.57M | Apr 15, 2024 |
| FY2023 | Jun 30, 2023 | $8.26M | Apr 15, 2024 |
| FY2023 | Mar 31, 2023 | $5.48M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $22.87M | Apr 15, 2024 |
| FY2023 | Sep 30, 2022 | $4.24M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $4.85M | Mar 30, 2023 |
| FY2021 | Dec 13, 2021 | $4.85M | Mar 15, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.59M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($33.54M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($28.32M) | Apr 3, 2025 |
| FY2023 | Sep 30, 2023 | ($19.45M) | Apr 15, 2024 |
| FY2023 | Jun 30, 2023 | ($13.27M) | Apr 15, 2024 |
| FY2023 | Mar 31, 2023 | ($7.95M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($18.96M) | Apr 15, 2024 |
| FY2023 | Sep 30, 2022 | ($14.27M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($10.67M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($4.07M) | Mar 15, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.92M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $15.50M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $23.70M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $18.92M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $31.40M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.76M | Mar 15, 2022 |
| FY2020 | Feb 29, 2020 | $61.02M | May 4, 2020 |
| FY2020 | Dec 31, 2019 | $2.6K | May 7, 2021 |
| FY2020 | Feb 28, 2019 | $65.65M | May 4, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.28M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $14.69M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $17.98M | Apr 3, 2025 |
| FY2023 | Sep 30, 2023 | $18.20M | Apr 15, 2024 |
| FY2023 | Jun 30, 2023 | $13.66M | Apr 15, 2024 |
| FY2023 | Mar 31, 2023 | $11.29M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $10.53M | Apr 15, 2024 |
| FY2023 | Sep 30, 2022 | $6.49M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.72M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.30M | Mar 15, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.65M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $812.6K | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $5.72M | Mar 30, 2026 |
| FY2023 | Sep 30, 2023 | ($12.81M) | Apr 15, 2024 |
| FY2023 | Jun 30, 2023 | ($1.82M) | Apr 15, 2024 |
| FY2023 | Mar 31, 2023 | $1.61M | Apr 15, 2024 |
| FY2024 | Jan 1, 2023 | $8.39M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $8.39M | Apr 15, 2024 |
| FY2023 | Sep 30, 2022 | $17.56M | Apr 15, 2024 |
| FY2023 | Dec 31, 2021 | $28.69M | Apr 15, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($184.14M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($164.27M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($134.35M) | Apr 3, 2025 |
| FY2023 | Sep 30, 2023 | ($125.00M) | Apr 15, 2024 |
| FY2023 | Jun 30, 2023 | ($113.65M) | Apr 15, 2024 |
| FY2023 | Mar 31, 2023 | ($101.95M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($95.09M) | Apr 15, 2024 |
| FY2023 | Sep 30, 2022 | ($85.86M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($66.83M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($58.31M) | Mar 15, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.44M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $13.48M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $23.37M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $18.52M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $29.69M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.76M | Mar 15, 2022 |
| FY2020 | Feb 29, 2020 | $69.3K | May 4, 2020 |
| FY2020 | Dec 31, 2019 | $193 | May 7, 2021 |
| FY2020 | Feb 28, 2019 | $313.0K | May 4, 2020 |
| FY2019 | Mar 19, 2018 | $0 | May 22, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (17) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Apr 3, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Apr 15, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Apr 15, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Apr 15, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.87M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 2.36M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 27.92M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | 20.45M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 14.43M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 9.23M | Mar 15, 2022 |
| FY2021 | Dec 14, 2020 | 9.23M | Mar 15, 2022 |
| FY2020 | Feb 29, 2020 | 2.70M | May 4, 2020 |
| FY2020 | Feb 28, 2019 | 2.60M | May 4, 2020 |